{"address1": "1900 Lake Park Drive", "address2": "Suite 380", "city": "Smyrna", "state": "GA", "zip": "30080", "country": "United States", "phone": "(678) 384-7220", "fax": "(678) 384-7281", "website": "https://www.geovax.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.", "fullTimeEmployees": 17, "companyOfficers": [{"maxAge": 1, "name": "Mr. David Alan Dodd", "age": 74, "title": "Chairman, President & CEO", "yearBorn": 1950, "fiscalYear": 2023, "totalPay": 384200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark J. Newman Ph.D.", "age": 69, "title": "Chief Scientific Officer", "yearBorn": 1955, "fiscalYear": 2023, "totalPay": 291500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kelly T. McKee Jr., M.D., M.P.H.", "age": 73, "title": "Chief Medical Officer", "yearBorn": 1951, "fiscalYear": 2023, "totalPay": 361034, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Harriet Latham Robinson Ph.D.", "age": 86, "title": "Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board", "yearBorn": 1938, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark W. Reynolds CPA", "age": 62, "title": "CFO & Corporate Secretary", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 348200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas  O'Brien", "title": "Vice President of Quality Systems & Compliance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jeffrey  Welch", "title": "Head of Process Development & Manufacturing Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John W. Sharkey Ph.D.", "age": 68, "title": "Vice President of Business Development", "yearBorn": 1956, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.0502, "open": 0.054, "dayLow": 0.054, "dayHigh": 0.054, "regularMarketPreviousClose": 0.0502, "regularMarketOpen": 0.054, "regularMarketDayLow": 0.054, "regularMarketDayHigh": 0.054, "beta": 3.07, "volume": 1006, "regularMarketVolume": 1006, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fiftyTwoWeekLow": 0.054, "fiftyTwoWeekHigh": 0.054, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "profitMargins": 0.0, "floatShares": 8895948, "bookValue": 0.988, "priceToBook": 0.054655872, "netIncomeToCommon": -24322050, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 0.054, "recommendationKey": "none", "totalCash": 8592523, "totalCashPerShare": 0.911, "ebitda": -24397688, "totalDebt": 0, "quickRatio": 3.504, "currentRatio": 4.167, "totalRevenue": 3090161, "revenuePerShare": 0.945, "returnOnAssets": -1.12097, "returnOnEquity": -2.76023, "grossProfits": -19249188, "freeCashflow": -19251946, "operatingCashflow": -27199906, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -2.0988, "financialCurrency": "USD", "symbol": "GOVXW", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketTime": 1743537600, "marketState": "PRE", "regularMarketChangePercent": 7.5697227, "regularMarketPrice": 0.054, "shortName": "GeoVax Labs, Inc.", "longName": "GeoVax Labs, Inc.", "exchange": "NCM", "messageBoardId": "finmb_12056751", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "regularMarketChange": 0.003800001, "regularMarketDayRange": "0.054 - 0.054", "fullExchangeName": "NasdaqCM", "fiftyTwoWeekLowChange": 0.0, "fiftyTwoWeekLowChangePercent": 0.0, "fiftyTwoWeekRange": "0.054 - 0.054", "fiftyTwoWeekHighChange": 0.0, "fiftyTwoWeekHighChangePercent": 0.0, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "hasPrePostMarketData": true, "displayName": "GeoVax Labs", "trailingPegRatio": null}